^
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
dinutuximab beta Sensitive: A1 - Approval
|
dinutuximab beta Sensitive: A1 - Approval
|
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
melphalan Sensitive: A1 - Approval
|
melphalan Sensitive: A1 - Approval
|
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
dinutuximab Sensitive: A1 - Approval
|
dinutuximab Sensitive: A1 - Approval
|
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
cyclophosphamide Sensitive: A1 - Approval
|
cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
Neuroblastoma
|
No biomarker
|
Neuroblastoma
|
naxitamab Sensitive: A1 - Approval
|
naxitamab Sensitive: A1 - Approval
|
ALK positive
|
Neuroblastoma
|
ALK positive
|
Neuroblastoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ALK R1275Q
|
Neuroblastoma
|
ALK R1275Q
|
Neuroblastoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ATRX mutation
|
Neuroblastoma
|
ATRX mutation
|
Neuroblastoma
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
ALK rearrangement + ALK R1275Q + TP53 mutation
|
Neuroblastoma
|
ALK rearrangement + ALK R1275Q + TP53 mutation
|
Neuroblastoma
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
PGBD5 overexpression
|
Neuroblastoma
|
PGBD5 overexpression
|
Neuroblastoma
|
cisplatin Sensitive: D – Preclinical
|
cisplatin Sensitive: D – Preclinical
|
PGBD5 overexpression
|
Neuroblastoma
|
PGBD5 overexpression
|
Neuroblastoma
|
AZD6738 Sensitive: D – Preclinical
|
AZD6738 Sensitive: D – Preclinical
|
PGBD5 underexpression
|
Neuroblastoma
|
PGBD5 underexpression
|
Neuroblastoma
|
AZD6738 Sensitive: D – Preclinical
|
AZD6738 Sensitive: D – Preclinical
|
ALK R1275Q
|
Neuroblastoma
|
ALK R1275Q
|
Neuroblastoma
|
TAE-684 Resistant: D – Preclinical
|
TAE-684 Resistant: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
panobinostat + GSK2816126 Sensitive: D – Preclinical
|
panobinostat + GSK2816126 Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
OTX015 Sensitive: D – Preclinical
|
OTX015 Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
JQ-1 + panobinostat Sensitive: D – Preclinical
|
JQ-1 + panobinostat Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
brigatinib Resistant: D – Preclinical
|
brigatinib Resistant: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
crizotinib Resistant: D – Preclinical
|
crizotinib Resistant: D – Preclinical
|
ALK F1174L
|
Neuroblastoma
|
ALK F1174L
|
Neuroblastoma
|
crizotinib Resistant: D – Preclinical
|
crizotinib Resistant: D – Preclinical
|
ALK F1174L
|
Neuroblastoma
|
ALK F1174L
|
Neuroblastoma
|
AZD3463 Sensitive: D – Preclinical
|
AZD3463 Sensitive: D – Preclinical
|
ALK F1174L
|
Neuroblastoma
|
ALK F1174L
|
Neuroblastoma
|
alectinib Sensitive: D – Preclinical
|
alectinib Sensitive: D – Preclinical
|
ALK amplification
|
Neuroblastoma
|
ALK amplification
|
Neuroblastoma
|
alectinib Sensitive: D – Preclinical
|
alectinib Sensitive: D – Preclinical
|
ALK F1245C
|
Neuroblastoma
|
ALK F1245C
|
Neuroblastoma
|
lorlatinib Sensitive: D – Preclinical
|
lorlatinib Sensitive: D – Preclinical
|
ALK F1174C
|
Neuroblastoma
|
ALK F1174C
|
Neuroblastoma
|
lorlatinib Sensitive: D – Preclinical
|
lorlatinib Sensitive: D – Preclinical
|
ALK F1174L
|
Neuroblastoma
|
ALK F1174L
|
Neuroblastoma
|
TAE-684 Sensitive: D – Preclinical
|
TAE-684 Sensitive: D – Preclinical
|
MYCN amplification + ALK rearrangement
|
Neuroblastoma
|
MYCN amplification + ALK rearrangement
|
Neuroblastoma
|
brigatinib Sensitive: D – Preclinical
|
brigatinib Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174V
|
Neuroblastoma
|
MYCN amplification + ALK F1174V
|
Neuroblastoma
|
brigatinib Sensitive: D – Preclinical
|
brigatinib Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174V
|
Neuroblastoma
|
MYCN amplification + ALK F1174V
|
Neuroblastoma
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|
NF1 underexpression
|
Neuroblastoma
|
NF1 underexpression
|
Neuroblastoma
|
binimetinib Sensitive: D – Preclinical
|
binimetinib Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174L
|
Neuroblastoma
|
MYCN amplification + ALK F1174L
|
Neuroblastoma
|
lorlatinib Sensitive: D – Preclinical
|
lorlatinib Sensitive: D – Preclinical
|
ALK D1091N
|
Neuroblastoma
|
ALK D1091N
|
Neuroblastoma
|
AZD3463 Sensitive: D – Preclinical
|
AZD3463 Sensitive: D – Preclinical
|
MYCN amplification + ALK rearrangement
|
Neuroblastoma
|
MYCN amplification + ALK rearrangement
|
Neuroblastoma
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|
MYCN amplification + ALK R1275Q
|
Neuroblastoma
|
MYCN amplification + ALK R1275Q
|
Neuroblastoma
|
lorlatinib Sensitive: D – Preclinical
|
lorlatinib Sensitive: D – Preclinical
|
ETV6-NTRK3 fusion
|
Neuroblastoma
|
ETV6-NTRK3 fusion
|
Neuroblastoma
|
TPX-0005 Sensitive: D – Preclinical
|
TPX-0005 Sensitive: D – Preclinical
|
CD276 expression
|
Neuroblastoma
|
CD276 expression
|
Neuroblastoma
|
B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical
|
B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical
|
TERT rearrangement
|
Neuroblastoma
|
TERT rearrangement
|
Neuroblastoma
|
OTX015 Sensitive: D – Preclinical
|
OTX015 Sensitive: D – Preclinical
|
ALK positive
|
Neuroblastoma
|
ALK positive
|
Neuroblastoma
|
CAR-T immunotherapy Sensitive: D – Preclinical
|
CAR-T immunotherapy Sensitive: D – Preclinical
|
NRAS Q61K
|
Neuroblastoma
|
NRAS Q61K
|
Neuroblastoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
DHODH inhibitor Sensitive: D – Preclinical
|
DHODH inhibitor Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
olaparib + MK-8776 Sensitive: D – Preclinical
|
olaparib + MK-8776 Sensitive: D – Preclinical
|
MYCN amplification
|
Neuroblastoma
|
MYCN amplification
|
Neuroblastoma
|
venetoclax + LY3295668 Sensitive: D – Preclinical
|
venetoclax + LY3295668 Sensitive: D – Preclinical
|
